Certain Bone Cements, Components Thereof and Products Containing the Same; Notice of Commission Determination Finding No Violation of Section 337; Termination of the Investigation, 5249 [2021-00996]
Download as PDF
Federal Register / Vol. 86, No. 11 / Tuesday, January 19, 2021 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1153]
Certain Bone Cements, Components
Thereof and Products Containing the
Same; Notice of Commission
Determination Finding No Violation of
Section 337; Termination of the
Investigation
International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission (‘‘Commission’’) has
determined to affirm in part, reverse in
part, and vacate in part the final initial
determination’s (‘‘ID’’) finding that no
violation of section 337 has occurred.
The investigation is terminated.
FOR FURTHER INFORMATION CONTACT:
Ronald A. Traud, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
205–3427. Copies of non-confidential
documents filed in connection with this
investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on (202)
205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on April 10, 2019, based on a complaint
filed by Heraeus Medical LLC of
Yardley, Pennsylvania, and Heraeus
Medical GmbH of Wehrheim, Germany
(collectively, ‘‘Complainants’’). 84 FR
14394–95 (Apr. 10, 2019). The
complaint alleges a violation of section
337 of the Tariff Act of 1930, as
amended, by reason of misappropriation
of trade secrets, the threat or effect of
which is to destroy or substantially
injure an industry in the United States
or to prevent the establishment of such
an industry. The complaint named the
following respondents: Zimmer Biomet
Holdings, Inc. of Warsaw, Indiana;
Biomet, Inc. of Warsaw, Indiana;
Zimmer Orthopaedic Surgical Products,
Inc. of Dover, Ohio; Zimmer Surgical,
Inc. of Dover, Ohio; Biomet France
S.A.R.L. of Valence, France; Biomet
Deutschland GmbH of Berlin, Germany;
Zimmer Biomet Deutschland GmbH of
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:19 Jan 17, 2021
Jkt 253001
Freiburg im Breisgau, Germany; Biomet
Europe B.V. of Dordrecht, Netherlands;
Biomet Global Supply Chain Center B.V.
of Dordrecht, Netherlands; Zimmer
Biomet Nederland B.V. of Dordrecht,
Netherlands; Biomet Orthopedics, LLC
of Warsaw, Indiana; and Biomet
Orthopaedics Switzerland GmbH of
Dietikon, Switzerland. The
Commission’s Office of Unfair Import
Investigations (‘‘OUII’’) also was named
as a party.
The investigation has terminated as to
respondents Zimmer Orthopaedic
Surgical Products, Inc. and Biomet
Europe B.V., Order No. 10 (May 23,
2019), unreviewed, Notice (June 14,
2019), and as to certain accused
products, Order No. 30 (Nov. 24, 2019),
unreviewed, Notice (Dec. 10, 2019).
Also, the first amended complaint and
notice of investigation were amended to
add three entities as respondents:
Zimmer US, Inc.; Zimmer, GmbH; and
Biomet Manufacturing, LLC. Order No.
18 (June 26, 2019), unreviewed, 84 FR
35884–85 (July 25, 2019). The remaining
respondents are referred to collectively
herein as ‘‘Zimmer Biomet.’’
On May 6, 2020, the presiding
administrative law judge (‘‘ALJ’’) issued
the final ID, which found that Zimmer
Biomet did not violate section 337. On
May 18, 2020, the parties filed petitions
for review of the final ID.
On July 13, 2020, the Commission
determined to review in part the final ID
and requested briefing from the parties
on the issues under review. In
particular, the Commission determined
to review the following: (1) The ALJ’s
findings and conclusions as to TS 1–35
and 121–23; and (2) the ALJ’s domestic
industry findings, including whether
there has been a substantial injury to the
alleged domestic industry. The
Commission also sought briefing from
the parties, interested government
agencies, and any other interested
parties on remedy, bonding, and the
public interest.
Having examined the record of this
investigation, including the final ID, the
petitions for review, the responses
thereto, and the written submissions in
response to the Commission’s request
for briefing, the Commission finds that
no violation of section 337 has occurred.
Specifically, the Commission finds that
the Complainants did not establish that
an industry in the United States exists
as required by section 337(a)(1)(A)(i)
and therefore did not establish injury to
a domestic industry. The investigation
is hereby terminated.
The Commission vote for this
determination took place on January 12,
2021.
PO 00000
Frm 00120
Fmt 4703
Sfmt 4703
5249
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: January 12, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–00996 Filed 1–15–21; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1200]
Certain Electronic Devices, Including
Streaming Players, Televisions, Set
Top Boxes, Remote Controllers, and
Components Thereof; Notice of a
Commission Determination Not To
Review an Initial Determination
Correcting the Notice of Investigation
International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission (‘‘Commission’’) has
determined not to review an initial
determination (‘‘ID’’) (Order No. 33),
granting the parties’ joint motion to
amend the notice of institution of the
investigation by clarifying that claims 2
and 4–5 of U.S. Patent No. 10,593,196
(‘‘the ’196 patent’’) are among the
domestic industry claims but are not
being asserted against any respondent
for purposes of infringement. The notice
of investigation is amended accordingly.
FOR FURTHER INFORMATION CONTACT: Carl
P. Bretscher, Esq., Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
205–2382. Copies of non-confidential
documents filed in connection with this
investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on (202)
205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on May 22, 2020, based on a complaint
SUMMARY:
E:\FR\FM\19JAN1.SGM
19JAN1
Agencies
[Federal Register Volume 86, Number 11 (Tuesday, January 19, 2021)]
[Notices]
[Page 5249]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-00996]
[[Page 5249]]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1153]
Certain Bone Cements, Components Thereof and Products Containing
the Same; Notice of Commission Determination Finding No Violation of
Section 337; Termination of the Investigation
AGENCY: International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission (``Commission'') has determined to affirm in part, reverse
in part, and vacate in part the final initial determination's (``ID'')
finding that no violation of section 337 has occurred. The
investigation is terminated.
FOR FURTHER INFORMATION CONTACT: Ronald A. Traud, Office of the General
Counsel, U.S. International Trade Commission, 500 E Street SW,
Washington, DC 20436, telephone (202) 205-3427. Copies of non-
confidential documents filed in connection with this investigation may
be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email
[email protected]. General information concerning the Commission may
also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on
this matter can be obtained by contacting the Commission's TDD terminal
on (202) 205-1810.
SUPPLEMENTARY INFORMATION: The Commission instituted this investigation
on April 10, 2019, based on a complaint filed by Heraeus Medical LLC of
Yardley, Pennsylvania, and Heraeus Medical GmbH of Wehrheim, Germany
(collectively, ``Complainants''). 84 FR 14394-95 (Apr. 10, 2019). The
complaint alleges a violation of section 337 of the Tariff Act of 1930,
as amended, by reason of misappropriation of trade secrets, the threat
or effect of which is to destroy or substantially injure an industry in
the United States or to prevent the establishment of such an industry.
The complaint named the following respondents: Zimmer Biomet Holdings,
Inc. of Warsaw, Indiana; Biomet, Inc. of Warsaw, Indiana; Zimmer
Orthopaedic Surgical Products, Inc. of Dover, Ohio; Zimmer Surgical,
Inc. of Dover, Ohio; Biomet France S.A.R.L. of Valence, France; Biomet
Deutschland GmbH of Berlin, Germany; Zimmer Biomet Deutschland GmbH of
Freiburg im Breisgau, Germany; Biomet Europe B.V. of Dordrecht,
Netherlands; Biomet Global Supply Chain Center B.V. of Dordrecht,
Netherlands; Zimmer Biomet Nederland B.V. of Dordrecht, Netherlands;
Biomet Orthopedics, LLC of Warsaw, Indiana; and Biomet Orthopaedics
Switzerland GmbH of Dietikon, Switzerland. The Commission's Office of
Unfair Import Investigations (``OUII'') also was named as a party.
The investigation has terminated as to respondents Zimmer
Orthopaedic Surgical Products, Inc. and Biomet Europe B.V., Order No.
10 (May 23, 2019), unreviewed, Notice (June 14, 2019), and as to
certain accused products, Order No. 30 (Nov. 24, 2019), unreviewed,
Notice (Dec. 10, 2019). Also, the first amended complaint and notice of
investigation were amended to add three entities as respondents: Zimmer
US, Inc.; Zimmer, GmbH; and Biomet Manufacturing, LLC. Order No. 18
(June 26, 2019), unreviewed, 84 FR 35884-85 (July 25, 2019). The
remaining respondents are referred to collectively herein as ``Zimmer
Biomet.''
On May 6, 2020, the presiding administrative law judge (``ALJ'')
issued the final ID, which found that Zimmer Biomet did not violate
section 337. On May 18, 2020, the parties filed petitions for review of
the final ID.
On July 13, 2020, the Commission determined to review in part the
final ID and requested briefing from the parties on the issues under
review. In particular, the Commission determined to review the
following: (1) The ALJ's findings and conclusions as to TS 1-35 and
121-23; and (2) the ALJ's domestic industry findings, including whether
there has been a substantial injury to the alleged domestic industry.
The Commission also sought briefing from the parties, interested
government agencies, and any other interested parties on remedy,
bonding, and the public interest.
Having examined the record of this investigation, including the
final ID, the petitions for review, the responses thereto, and the
written submissions in response to the Commission's request for
briefing, the Commission finds that no violation of section 337 has
occurred. Specifically, the Commission finds that the Complainants did
not establish that an industry in the United States exists as required
by section 337(a)(1)(A)(i) and therefore did not establish injury to a
domestic industry. The investigation is hereby terminated.
The Commission vote for this determination took place on January
12, 2021.
The authority for the Commission's determination is contained in
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: January 12, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021-00996 Filed 1-15-21; 8:45 am]
BILLING CODE 7020-02-P